Trial Profile

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucravacitinib (Primary)
Indications Plaque psoriasis
Focus Adverse reactions; Pharmacodynamics
Acronyms POETYK Long-Term Extension; POETYK PSO-LTE
Sponsors Bristol-Myers Squibb

Most Recent Events

20 Oct 2025 The protocol has been amended to addition in Pharmacodynamics primary endpoints and treatment of Arms
16 Feb 2025 According to a Bristol-Myers Squibb Media Release, new five-year result data were presented at the Winter Clinical Dermatology Conference Hawaii (WCH) in Big Island, Waikoloa Village, HI taking place February 14-19, 2025.
16 Feb 2025 New five-year result presented in the Bristol-Myers Squibb Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com